Sign in
CompletedPhase 2

Thrombosomes® in Acute Thoracic Aortic Dissections

Key facts

Who runs it
Jakob Stensballe, MD, PhD
Where
Denmark1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
41 people enrolled
Started
15 Mar 2023
Ended
11 Apr 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Thrombosomes®
  • Standard platelet concentrate
Record updated
7 May 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Patient eligible for emergency surgery on cardiopulmonary bypass pump for acute thoracic aortic dissections
  • Age ≥ 18 years

Who cannot take part

  • Withdrawal from active therapy
  • Known hypersensitivity to TBX: the active substance, any of the excipients
  • Pregnancy (non-pregnancy confirmed by patient being postmenopausal (women >55 years of age) or having a negative urine-hCG)
  • Documented refusal of blood transfusion
  • Aortic dissection due to trauma

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The hypothesis is that administration of Thrombosomes® (TBX®) as hemostatic support when terminating the cardiopulmonary bypass (CPB) in patients undergoing emergency surgery for acute thoracic aortic dissection (aTAD) is safe and least as effective when compared to standard Platelet Concentrates (stPC).

The 2 groups in the trial

  • Thrombosomes®Treatment being tested

    Thrombosomes® (TBX®) up to 3 doses

  • Standard platelet concentrateExisting treatment, for comparison

    Standard platelet concentrate up to 3 doses

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Feasibility and Safety of Thrombosomes® on Time to Hemostasis in Patients Undergoing Emergency Surgery for Thoracic Aortic Dissections - a Randomized, Controlled, Open-label Investigator-initiated Pilot Trial
Record updated
7 May 2024